Indication
B-Cell Lymphoma Refractory
1 clinical trial
1 drug
Clinical trial
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2022-04-19